Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovac Depot dose-finding in Phleum pratense allergic rhinoconjunctivitis
NCT01567306Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Oct 2011
- Primary completion
- Apr 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of allergovac depot in allergic rhinoconjunctivitis (ARC), sponsored by ROXALL Medizin GmbH. Started Oct 2011; status: completed.
02
Drugs
allergovac depot
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01567306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567306.